MX2023015444A - Inmunocitocinas a base de interleucina-15. - Google Patents

Inmunocitocinas a base de interleucina-15.

Info

Publication number
MX2023015444A
MX2023015444A MX2023015444A MX2023015444A MX2023015444A MX 2023015444 A MX2023015444 A MX 2023015444A MX 2023015444 A MX2023015444 A MX 2023015444A MX 2023015444 A MX2023015444 A MX 2023015444A MX 2023015444 A MX2023015444 A MX 2023015444A
Authority
MX
Mexico
Prior art keywords
interleukin
immunocytokines
based immunocytokines
superagonists
vectors
Prior art date
Application number
MX2023015444A
Other languages
English (en)
Spanish (es)
Inventor
Roger Renzo Beerli
Ulrich Moebius
Lorenz Waldmeier
David Béchard
Irena Adkins
Lukas Bammert
Sadilkova Lenka Kyrych
Martynoff Guy Luc Michel De
Zuzana Antosová
Sárka Pechoucková
Iva Valentová
Simona Hosková
Eva Nedvedova
Original Assignee
Cytune Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytune Pharma filed Critical Cytune Pharma
Publication of MX2023015444A publication Critical patent/MX2023015444A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023015444A 2021-06-23 2022-06-23 Inmunocitocinas a base de interleucina-15. MX2023015444A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21181271 2021-06-23
EP22163748 2022-03-23
PCT/EP2022/067236 WO2022268983A2 (en) 2021-06-23 2022-06-23 Interleukin-15 based immunocytokines

Publications (1)

Publication Number Publication Date
MX2023015444A true MX2023015444A (es) 2024-04-29

Family

ID=82361370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015444A MX2023015444A (es) 2021-06-23 2022-06-23 Inmunocitocinas a base de interleucina-15.

Country Status (10)

Country Link
US (1) US20240294594A1 (https=)
EP (1) EP4359428A2 (https=)
JP (1) JP2024524891A (https=)
KR (1) KR20240024242A (https=)
AU (1) AU2022296794A1 (https=)
BR (1) BR112023027312A2 (https=)
CA (1) CA3221886A1 (https=)
IL (1) IL309533A (https=)
MX (1) MX2023015444A (https=)
WO (1) WO2022268983A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3444271T (pt) 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
US20230030674A1 (en) * 2019-12-06 2023-02-02 Sotio Biotech A.S. Humanized cldn18.2 antibodies
WO2025177263A1 (en) * 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20100082438A1 (en) 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US20110318302A1 (en) 2009-01-07 2011-12-29 Kathrin Schwager Cancer Treatment
JP6594855B2 (ja) * 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
AU2016365114A1 (en) 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
MA52289A (fr) * 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
AU2019359475A1 (en) * 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
CA3153542A1 (en) * 2019-09-25 2021-04-01 Leto Laboratories Co., Ltd Recombinant interleukin-15 analog

Also Published As

Publication number Publication date
JP2024524891A (ja) 2024-07-09
WO2022268983A3 (en) 2023-04-06
CA3221886A1 (en) 2022-12-29
KR20240024242A (ko) 2024-02-23
WO2022268983A2 (en) 2022-12-29
IL309533A (en) 2024-02-01
BR112023027312A2 (pt) 2024-03-12
EP4359428A2 (en) 2024-05-01
US20240294594A1 (en) 2024-09-05
AU2022296794A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
MX2023015444A (es) Inmunocitocinas a base de interleucina-15.
MY193353A (en) Anti-vegf protein compositions and methods for producing the same
MX2021002415A (es) Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
MX2022007575A (es) Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
ZA202309516B (en) Anti-ccr8 antibodies
WO2019209885A3 (en) Enzyme engineering to alter the functional repertoire of cannabinoid synthases
MY207121A (en) Anti-ror antibody constructs
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
MX2023014628A (es) Vectores de expresion, vectores libres de secuencias bacterianas y metodos para fabricar y usar los mismos.
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2023005841A (es) Anticuerpos anti-marco y usos de estos.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2025000643A (es) Nanomateriales que comprenden trioles
WO2020079448A9 (en) Novel cancer antigens and methods
MX2021006922A (es) Constructo multigenico para la expresión de proteínas inmunoduladoras y métodos de uso.
PH12023550112A1 (en) Anti-notch2 antibodies and methods of use
MX2023011919A (es) Construcciones de proteinas de union a antigenos y anticuerpos y usos de estos.
WO2018203737A3 (ko) 단백질 반감기를 증가시키는 방법
MX2023007302A (es) Anticuerpos contra la integrina alfa 11 beta 1.
MX2026002804A (es) Aticuerpos anti-cd30l y usos de los mismos
WO2023064280A3 (en) Compositions comprising hiv envelopes to induce hiv-1 antibodies
WO2021226179A3 (en) Anti-sars-cov-2 spike protein antibodies and methods of use
MX2025011554A (es) Proteinas de union a trop2 y usos de estas
MX2024015647A (es) Conjugados farmaco-anticuerpo anti-cd19